Evidence map›Paper›PMID 38088952›Full record

ReviewBiochemistry and biophysics reports2024

miRNAs as biomarkers of therapeutic response to HER2-targeted treatment in breast cancer: A systematic review.

Thanh Hoa Vo, Esam El-Sherbieny Abdelaal, Emmet Jordan, Orla O'Donovan, Edel A McNeela, Jai Prakash Mehta, Sweta Rani

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biochemistry and biophysics reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Thanh Hoa VoDepartment of Science, School of Science and Computing, South East Technological University, Cork Road, Waterford, X91 K0EK, Ireland.
Esam El-Sherbieny AbdelaalDepartment of Oncology, UPMC Whitfield Hospital, Cork Road, X91 DH9W, Waterford, Ireland.
Emmet JordanDepartment of Oncology, University Hospital Waterford, Dunmore Road, X91 ER8E, Waterford, Ireland.
Orla O'DonovanDepartment of Science, School of Science and Computing, South East Technological University, Cork Road, Waterford, X91 K0EK, Ireland.
Edel A McNeelaDepartment of Science, School of Science and Computing, South East Technological University, Cork Road, Waterford, X91 K0EK, Ireland.
Jai Prakash MehtaDepartment of Applied Science, South East Technological University, Kilkenny Road, R93 V960, Carlow, Ireland.
Sweta RaniDepartment of Science, School of Science and Computing, South East Technological University, Cork Road, Waterford, X91 K0EK, Ireland.
Munster Technological University · IEUniversity Hospital Waterford · IESouth East Technological University · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is the most common type of lethal cancer in women globally. Women have a 1 in 8 chance of developing breast cancer in their lifetime. Among the four primary molecular subtypes (luminal A, luminal B, HER2+, and triple-negative), HER2+ accounts for 20-25 % of all breast cancer and is rather aggressive. Although the treatment outcome of HER2+ breast cancer patients has been significantly improved with anti-HER2 agents, primary and acquired drug resistance present substantial clinical issues, limiting the benefits of HER2-targeted treatment. MicroRNAs (miRNAs) play a central role in regulating acquired drug resistance. miRNA are single-stranded, non-coding RNAs of around 20-25 nucleotides, known for essential roles in regulating gene expression at the post-transcriptional level. Increasing evidence has demonstrated that miRNA-mediated alteration of gene expression is associated with tumorigenesis, metastasis, and tumor response to treatment. Comprehensive knowledge of miRNAs as potential markers of drug response can help provide valuable guidance for treatment prognosis and personalized medicine for breast cancer patients.

Indexed as

Drug resistanceDrug sensitivityHER2-Positive breast cancerHER2 target therapymiRNAsTreatment response

Identifiers

PMID38088952
PMCPMC10711031
OpenAlexW4389069250

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.